A controlled trial of a protein-free liver extract in the treatment of chronic liver disease.

A double-blind trial of a protein-free liver extract (Ripason) which was administered both orally and intramuscularly is described in 20 patients with stable cirrhosis. Control and treated groups were similar in composition except for age. Both groups showed some symptomatic improvement during the trial. Fewer patients were recorded as worse on Ripason but no significant changes in body weight, haemoglobin, or liver function tests could be detected.

RCT Entities:   Population Interventions Outcomes